CureDuchenne Ventures

investment firm

Details

Operating Status
Active
Investor Type
PE

Investments

Number of Investments
Number of Lead Investments
16
4
CureDuchenne Ventures has made 16 investments. Their most recent investment was on Jun 7, 2022, when Code Biotherapeutics raised $75M.
Date Company Name
Round Money Raised Industry Lead Investor
Series A $75M Biotechnology
Dec 22, 2021 Gennao Bio
Series A $1M Biotechnology Yes
Aug 5, 2021 Pepgen
Series Unknown $112.50M Biotechnology
Seed $10M Biotechnology
Series B $116M Biotechnology

Employee Profiles

Number of Employee Profiles
2
CureDuchenne Ventures has 2 current employee profiles, including Executive Debra Miller
Executive
Employee

Exits

CureDuchenne Ventures has had 7 exits. CureDuchenne Ventures most notable exits include Pepgen ,   Entrada Therapeutics

Date Company Name Exit Type Industry
May 6, 2022 Pepgen IPO Biotechnology Detail
Oct 29, 2021 Entrada Therapeutics IPO Biotechnology Detail
Mar 26, 2021 Edgewise Therapeutics IPO Biopharma Detail
Dec 10, 2020 4D Molecular Therapeutics IPO Biotechnology Detail
Jun 11, 2020 Avidity Biosciences IPO Biotechnology Detail